secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0000950170-23-038733
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Therapeutics Q2 2023 net loss $30.7M; cash $231.4M to fund operations to end of 2025
--------------------------------------------------------------------------------

- Net loss $30.7M ($0.69 per share) vs $24.7M ($0.63) in Q2 2022; R&D expenses $20.6M.
- Cash and marketable securities $231.4M as of June 30, 2023; expected runway to end of 2025.
- Revenue reversed $(2.5)M vs $3.2M a year ago due to $5.3M cumulative catch-up on Acadia collaboration.
- STK-001: additional data from MONARCH/ADMIRAL and OLEs expected Q1 2024 to inform Phase 3 design.
- STK-002: UK MHRA authorized Phase 1 OSPREY study for ADOA; enrollment in FALCON natural history completed (n=48).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000095017023038733/0000950170-23-038733-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000095017023038733/stok-20230807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-038733

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer